Effects of vancomycin versus nafcillin in enhancing killing of methicillin-susceptible Staphylococcus aureus causing bacteremia by human cathelicidin LL-37

被引:0
作者
J. Le
Q. Dam
M. Schweizer
W. Thienphrapa
V. Nizet
G. Sakoulas
机构
[1] University of California San Diego,Skaggs School of Pharmacy and Pharmaceutical Sciences
[2] University of California San Diego School of Medicine,undefined
[3] Iowa City VA Health Care System,undefined
[4] University of Iowa Carver College of Medicine,undefined
来源
European Journal of Clinical Microbiology & Infectious Diseases | 2016年 / 35卷
关键词
Vancomycin; Linezolid; Daptomycin; Survival Ratio; Ceftaroline;
D O I
暂无
中图分类号
学科分类号
摘要
Recent studies have demonstrated that anti-staphylococcal beta-lactam antibiotics, like nafcillin, render methicillin-resistant Staphylococcus aureus (MRSA) more susceptible to killing by innate host defense peptides (HDPs), such as cathelicidin LL-37. We compared the effects of growth in 1/4 minimum inhibitory concentration (MIC) of nafcillin or vancomycin on the LL-37 killing of 92 methicillin-susceptible S. aureus (MSSA) isolates. For three randomly selected strains among these, we examined the effects of nafcillin, vancomycin, daptomycin, or linezolid on LL-37 killing and autolysis. Growth in the presence of subinhibitory nafcillin significantly enhanced LL-37 killing of MSSA compared to vancomycin and antibiotic-free controls. Nafcillin also reduced MSSA production of the golden staphylococcal pigment staphyloxanthin in 39 % of pigmented strains vs. 14 % for vancomycin. Among the antibiotics tested, only nafcillin resulted in significantly increased MSSA autolysis. These studies point to additional mechanisms of anti-staphylococcal activity of nafcillin beyond direct bactericidal activity, properties that vancomycin and other antibiotic classes do not exhibit. The ability of nafcillin to enhance sensitivity to innate HDPs may contribute to its superior effectiveness against MSSA, as suggested by studies comparing clinical outcomes to vancomycin treatment.
引用
收藏
页码:1441 / 1447
页数:6
相关论文
共 206 条
  • [1] Schweizer ML(2010)Empiric antibiotic therapy for Staphylococcus aureus bacteremia may not reduce in-hospital mortality: a retrospective cohort study PLoS One 5 340-347
  • [2] Furuno JP(2011)Antibiotic choice may not explain poorer outcomes in patients with Staphylococcus aureus bacteremia and high vancomycin minimum inhibitory concentrations J Infect Dis 204 192-197
  • [3] Harris AD(2008)Outcome of vancomycin treatment in patients with methicillin-susceptible Staphylococcus aureus bacteremia Antimicrob Agents Chemother 52 1760-1765
  • [4] Johnson JK(2013)The empirical combination of vancomycin and a beta-lactam for Staphylococcal bacteremia Clin Infect Dis 57 279-196
  • [5] Shardell MD(2011)Comparative effectiveness of nafcillin or cefazolin versus vancomycin in methicillin-susceptible Staphylococcus aureus bacteremia BMC Infect Dis 11 190-5126
  • [6] McGregor JC(2007)Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis-dependent patients with methicillin-susceptible Staphylococcus aureus bacteremia Clin Infect Dis 44 5122-47
  • [7] Thom KA(2011)Is cefazolin inferior to nafcillin for treatment of methicillin-susceptible Staphylococcus aureus bacteremia? Antimicrob Agents Chemother 55 41-35
  • [8] Sakoulas G(2009)The roles of cathelicidin LL-37 in immune defences and novel clinical applications Curr Opin Hematol 16 22-514
  • [9] Perencevich EN(2012)A comprehensive summary of LL-37, the factotum human cathelicidin peptide Cell Immunol 280 504-1861
  • [10] Holmes NE(2013)Cathelicidins: peptides with antimicrobial, immunomodulatory, anti-inflammatory, angiogenic, anticancer and procancer activities Curr Protein Pept Sci 14 1854-3739